12a488c6-c319-4f40-9f62-82e74773370c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V1+0.400
- DNA_REPAIR+0.300
- MITOTIC_SPINDLE+0.300
- PROTEIN_SECRETION+0.300
- SPERMATOGENESIS+0.300
- HEDGEHOG_SIGNALING+0.200
- MYC_TARGETS_V2+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
Top 10 suppressed
- ANGIOGENESIS-0.300
- FATTY_ACID_METABOLISM-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- ADIPOGENESIS-0.200
- BILE_ACID_METABOLISM-0.200
- CHOLESTEROL_HOMEOSTASIS-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
- IL2_STAT5_SIGNALING-0.200
- KRAS_SIGNALING_DN-0.200
- KRAS_SIGNALING_UP-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 63f6d3e9-3f4b-44fa-8e48-980c70b7e4f1 | — | — | 0.787 |
| 2 | MDT-AP-1146 | Med | Medulloblastoma | 0.778 |
| 3 | 0f095e03-de38-4be9-874c-c58893e031d9 | — | — | 0.759 |
| 4 | DRR168611 | — | — | 0.757 |
| 5 | SRR15069617 | — | — | 0.753 |
| 6 | SRR934937 | — | — | 0.751 |
| 7 | TCGA-77-7138-01A-41R-2045-07 | — | cohortSQ1 | 0.745 |
| 8 | TCGA-ZF-A9RN-01A-11R-A42T-07 | — | — | 0.742 |
| 9 | sclc239860_S81.txt | — | cohortSC | 0.741 |
| 10 | SRR22247243 | — | cohortSC | 0.740 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |